Latest receivables for KBYPF: $34B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Kobayashi Pharmaceutical , Ltd. (KBYPF) currently reports a receivables of $34B as of June 2026. That compares with $33B in the prior-year period — up 2.7% year over year. Use the charts on this page to explore Kobayashi Pharmaceutical , Ltd.'s receivables history and peer comparisons.
Kobayashi Pharmaceutical , Ltd.'s receivables increased from $33B to $34B — a 2.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Kobayashi Pharmaceutical , Ltd. reported $34B in receivables as of June 2026. That compares with $33B in the prior-year period — up 2.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $34B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kobayashi Pharmaceutical , Ltd., and consider following KBYPF for alerts when major investors trade the stock.